CTNM Stock Analysis: Contineum Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 546m USD | 12M Return: 64.1% | US21217B1008 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.62M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 2.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Contineum Therapeutics, Inc. (NASDAQ: CTNM) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing small-molecule therapies for neuroscience, inflammation, and immunology indications. Its lead candidate, PIPE-791, is a brain-penetrant inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) being studied for idiopathic pulmonary fibrosis and chronic pain, while its second program, PIPE-307, is a muscarinic type 1 receptor inhibitor being evaluated for depression and relapse-remitting multiple sclerosis. The company was originally incorporated in 2009 as Pipeline Therapeutics, Inc. before adopting its current name in November 2023.
As a clinical-stage biopharmaceutical company, Contineum has no approved or commercialized products, and its value proposition centers on advancing its drug pipeline through human clinical trials with the goal of eventual regulatory approval or partnership. Small-molecule therapeutics, which Contineum specializes in, are typically orally administered compounds that are generally less complex to manufacture and often more cost-efficient to produce than large-molecule biologics, though they must still clear multi-year FDA trial phases before reaching market.
- PIPE-791 Phase 1 data readout in IPF and chronic pain trials
- Cash burn accelerates as clinical pipeline expansion continues
- PIPE-307 advances in depression and multiple sclerosis indications
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA 4.23 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.21 > 3% & CFO -53.0m > Net Income -57.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 37.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.5m) vs 12m ago 44.69% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.13%; Δ -0.13% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 242.6m - Total Current Liabilities 6.53m) / Total Assets 250.4m |
| B: -0.83 (Retained Earnings -207.0m / Total Assets 250.4m) |
| C: -0.31 (EBIT TTM -66.4m / Avg Total Assets 216.6m) |
| D: 22.38 (Book Value of Equity 239.7m / Total Liabilities 10.7m) |
| Altman-Z'' = 24.93 = AAA |
As of August 26, 2026, the stock is trading at USD 17.05 with a total of 724,748 shares traded. Over the past week, the price has changed by +17.59%, over one month by +23.02%, over three months by +24.45% and over the past year by +64.10%.
Current recommended Stop Loss: 14.90 (which is 12.6% or 2 ATR below the current price).
Contineum Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy CTNM.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.1 | 35.7% |
P/S = 11.147
P/B = 2.2777
Revenue TTM = 0.0 USD
EBIT TTM = -66.4m USD
EBITDA TTM = -66.0m USD
Long Term Debt = 4.18m USD (estimated: total debt 6.57m - short term 2.39m)
Short Term Debt = 2.39m USD (from shortTermDebt, last quarter)
Debt = 6.57m USD (from shortLongTermDebtTotal, last quarter) (leases 6.57m already included)
Net Debt = -230.0m USD (calculated: Debt 6.57m - CCE 236.6m)
Enterprise Value = 315.5m USD (545.5m + Debt 6.57m - CCE 236.6m)
Interest Coverage Ratio = unknown (Ebit TTM -66.4m / Interest Expense TTM 0.0)
EV/FCF = -5.90x (Enterprise Value 315.5m / FCF TTM -53.5m)
FCF Yield = -16.94% (FCF TTM -53.5m / Enterprise Value 315.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 323k) / Revenue TTM)
Tobins Q-Ratio = 1.26 (Enterprise Value 315.5m / Total Assets 250.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.57m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -52.4m (EBIT -66.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 37.17 (Total Current Assets 242.6m / Total Current Liabilities 6.53m)
Debt / Equity = 0.03 (Debt 6.57m / totalStockholderEquity, last quarter 239.7m)
Debt / EBITDA = 3.48 (negative EBITDA) (Net Debt -230.0m / EBITDA -66.0m)
Debt / FCF = 4.30 (negative FCF - burning cash) (Net Debt -230.0m / FCF TTM -53.5m)
Total Stockholder Equity = 232.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.57% (Net Income -57.6m / Total Assets 250.4m)
RoE = -24.73% (Net Income TTM -57.6m / Total Stockholder Equity 232.8m)
RoCE = -28.01% (EBIT -66.4m / Capital Employed (Equity 232.8m + L.T.Debt 4.18m))
RoIC = -21.30% (negative operating profit) (NOPAT -52.4m / Invested Capital 246.2m)
WACC = 10.16% (E(545.5m)/V(552.1m) * Re(10.28%) + D(6.57m)/V(552.1m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.02 | Cagr: 18.19%
[DCF] Fair Price = unknown (Cash Flow -53.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.48 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.45 | Chg30d=-6.00% | Revisions=+70% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.56 | Chg30d=+5.55% | Revisions=+25% | GrowthEPS=+28.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.80 | Chg30d=+0.95% | Revisions=+44% | GrowthEPS=-15.5% | GrowthRev=-73.4%
[Analyst] Revisions Ratio: +71% (up=13, down=1)